{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:58:19Z","timestamp":1786121899376,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001075","name":"Channel 7 Children's Research Foundation","doi-asserted-by":"publisher","award":["171412"],"award-info":[{"award-number":["171412"]}],"id":[{"id":"10.13039\/501100001075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","award":["MCR2257"],"award-info":[{"award-number":["MCR2257"]}],"id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","award":["022212"],"award-info":[{"award-number":["022212"]}],"id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009843","name":"South Australian Health and Medical Research Institute Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011302","name":"Children's Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011025","name":"Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000328","name":"Leukaemia Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020670","name":"Cancer Council Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000947","name":"Australian Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neo.2026.101337","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:27:52Z","timestamp":1784723272000},"page":"101337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-7602","authenticated-orcid":false,"given":"Laura N.","family":"Eadie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"McDougal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-4081","authenticated-orcid":false,"given":"Elias","family":"Lagonik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin E.","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8990-2574","authenticated-orcid":false,"given":"Elyse C.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tace S.","family":"Conlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-6943","authenticated-orcid":false,"given":"Jacqueline","family":"Rehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-1824","authenticated-orcid":false,"given":"John B.","family":"Bruning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-1779","authenticated-orcid":false,"given":"Andrew S.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-333X","authenticated-orcid":false,"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2026.101337_bib0001","unstructured":"Bethesda, M.N. C.I. Surveillance Research Program, National Cancer Institute: sEER*Explorer: an interactive website for SEER cancer statistics, Accessed Last accessed April 17, 2026."},{"key":"10.1016\/j.neo.2026.101337_bib0002","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2026.101337_bib0003","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome\u2013Like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101337_bib0004","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2026.101337_bib0005","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1182\/blood.2023023120","article-title":"Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain","volume":"143","author":"van Outersterp","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101337_bib0006","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2026.101337_bib0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41408-022-00613-9","article-title":"Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins","volume":"12","author":"Steiml\u00e9","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.neo.2026.101337_bib0008","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukaemia","volume":"632","author":"P\u00f6l\u00f6nen","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.neo.2026.101337_bib0009","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3324\/haematol.2019.231720","article-title":"Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols","volume":"105","author":"Cario","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.neo.2026.101337_bib0010","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.3900","article-title":"Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia","volume":"49","author":"Seki","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2026.101337_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010300","article-title":"RaScALL: rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)","volume":"18","author":"Rehn","year":"2022","journal-title":"PLoS. Genet."},{"key":"10.1016\/j.neo.2026.101337_bib0012","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","article-title":"Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study","volume":"8","author":"den Boer","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.neo.2026.101337_bib0013","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome\u2013like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.neo.2026.101337_bib0014","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/leu.2008.80","article-title":"Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies","volume":"22","author":"Quintas-Cardama","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2026.101337_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101337_bib0016","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/j.clml.2025.09.010","article-title":"Tyrosine kinase inhibitors during frontline therapy in adults with acute lymphoblastic leukemia with ABL-class rearrangements","volume":"26","author":"Braish","year":"2026","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"10.1016\/j.neo.2026.101337_bib0017","article-title":"Philadelphia-like genetic rearrangements in adults with B-cell ALL: refractoriness to chemotherapy and response to tyrosine kinase inhibitor in ABL class rearrangements","volume":"7","author":"Senapati","year":"2023","journal-title":"JCo Precis. Oncol."},{"key":"10.1016\/j.neo.2026.101337_bib0018","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101337_bib0019","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.17093","article-title":"Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion","volume":"191","author":"Moorman","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.neo.2026.101337_bib0020","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.neo.2026.101337_bib0021","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children's oncology Group trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101337_bib0022","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101337_bib0023","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2014.256","article-title":"Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment","volume":"29","author":"Yeung","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2026.101337_bib0024","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-011-0910-z","article-title":"RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations","volume":"94","author":"Inokuchi","year":"2011","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.neo.2026.101337_bib0025","first-page":"1779","article-title":"T315I mutation in ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports","volume":"32","author":"Watanabe","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.neo.2026.101337_bib0026","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.23666","article-title":"Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors","volume":"113","author":"Jones","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.neo.2026.101337_bib0027","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neo.2026.101337_bib0028","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.neo.2026.101337_bib0029","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.neo.2026.101337_bib0030","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2026.101337_bib0031","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2026.101337_bib0032","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.2024025800","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia","volume":"145","author":"Luskin","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101337_bib0033","doi-asserted-by":"crossref","first-page":"13423","DOI":"10.18632\/oncotarget.24393","article-title":"The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro","volume":"9","author":"Eadie","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.neo.2026.101337_bib0034","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2026.101337_bib0035","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41375-024-02314-7","article-title":"The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib","volume":"38","author":"Leske","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2026.101337_bib0036","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-024-02353-0","article-title":"Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib","volume":"38","author":"Leyte-Vidal","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2026.101337_bib0037","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024776","article-title":"Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy","volume":"144","author":"Eadie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101337_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100109","article-title":"Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain","volume":"2","author":"Lagonik","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.neo.2026.101337_bib0039","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.neo.2026.101337_bib0040","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.neo.2026.101337_bib0041","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/ng0398-280","article-title":"An intramolecular SH3-domain interaction regulates c-abl activity","volume":"18","author":"Baril\u00e1","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2026.101337_bib0042","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor Asciminib with Ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2026.101337_bib0043","unstructured":"Mitelman F, J. B. a. M. F. E. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (2024) https:\/\/mitelmandatabase.isb-cgc.org, (Accessed 15\/10\/2024)."},{"key":"10.1016\/j.neo.2026.101337_bib0044","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1074\/jbc.RA118.004732","article-title":"Structural insights into the tyrosine phosphorylation-mediated inhibition of SH3 domain-ligand interactions","volume":"294","author":"Mer\u0151","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neo.2026.101337_bib0045","doi-asserted-by":"crossref","first-page":"eadt5931","DOI":"10.1126\/scisignal.adt5931","article-title":"Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib","volume":"18","author":"Muratcioglu","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neo.2026.101337_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003863","article-title":"The SH2 domain regulates c-abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion","volume":"10","author":"D\u00f6lker","year":"2014","journal-title":"PLoS. Comput. Biol."},{"key":"10.1016\/j.neo.2026.101337_bib0047","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molcel.2011.03.004","article-title":"Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms","volume":"42","author":"Jura","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neo.2026.101337_bib0048","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00277-024-06142-8","article-title":"Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a ph\u2009+\u2009ALL patient","volume":"104","author":"Cullot","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.neo.2026.101337_bib0049","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1038\/s41467-024-51801-z","article-title":"AlphaFold predictions of fold-switched conformations are driven by structure memorization","volume":"15","author":"Chakravarty","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2026.101337_bib0050","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/s41467-024-46715-9","article-title":"High-throughput prediction of protein conformational distributions with subsampled AlphaFold2","volume":"15","author":"Monteiro da Silva","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:51:36Z","timestamp":1786085496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"alternative-id":["S1476558626000679"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101337","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101337"}}